Home › Companies › ARBUTUS BIOPHARMA CORP. › 2023-2024
Compiled from SEC Form N-PX filings and ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 28, 2024 (Item 5.07 on EDGAR). Page generated November 1, 2026.
Meeting of May 22, 2024: 9 items on ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 28, 2024: 2 approved · 7 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore ARBUTUS BIOPHARMA CORP. in the interactive database Compare manager voting policies
These tallies are ARBUTUS BIOPHARMA CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Frank Torti, M.D. | 116,514,685 | -- | -- | 6,089,738 | 24,915,140 | 95% | Not verified | — |
| Elect Director: Michael J. McElhaugh | 110,465,378 | -- | -- | 12,139,045 | 24,915,140 | 90% | Not verified | — |
| Elect Director: Daniel Burgess | 110,133,889 | -- | -- | 12,470,534 | 24,915,140 | 90% | Not verified | — |
| Elect Director: Richard C. Henriques | 109,654,719 | -- | -- | 12,949,704 | 24,915,140 | 89% | Not verified | — |
| Elect Director: Keith Manchester, M.D. | 105,954,077 | -- | -- | 16,650,346 | 24,915,140 | 86% | Not verified | — |
| Elect Director: James Meyers | 110,186,534 | -- | -- | 12,417,889 | 24,915,140 | 90% | Not verified | — |
| Elect Director: Melissa V. Rewolinski, Ph.D. | 111,055,063 | -- | -- | 11,549,360 | 24,915,140 | 91% | Not verified | — |
| 3. To approve, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular | 99,284,557 | 13,548,318 | 9,771,548 | -- | 24,915,140 | 88% | Approved | — |
| 4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 146,351,847 | 648,515 | 519,201 | -- | -- | 99.5% | Approved | — |
Source: ARBUTUS BIOPHARMA CORP., Form 8-K, filed with the SEC on May 28, 2024 — read the filing on EDGAR.
Each item below shows how the 113 asset managers that disclosed a ARBUTUS BIOPHARMA CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARBUTUS BIOPHARMA CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Daniel Burgess
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Daniel Burgess”): 110,133,889 for, 12,470,534 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 18,194,797 for, 216,415 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,498,193 | 0 | 0 | 84,361 | Mixed |
| Equitable | 572,378 | 0 | 0 | 96,040 | Mixed |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 125,425 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 19,699 | Withhold |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
| Federated Hermes | 11,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Frank Torti, M.D.
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Frank Torti, M.D.”): 116,514,685 for, 6,089,738 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 18,402,088 for, 9,124 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,582,554 | 0 | 0 | 0 | For |
| Equitable | 668,418 | 0 | 0 | 0 | For |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 125,425 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
| Federated Hermes | 11,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: James Meyers
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: James Meyers”): 110,186,534 for, 12,417,889 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 18,214,496 for, 196,716 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,498,193 | 0 | 0 | 84,361 | Mixed |
| Equitable | 572,378 | 0 | 0 | 96,040 | Mixed |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 125,425 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
| Federated Hermes | 11,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 2 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Keith Manchester, M.D.
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Keith Manchester, M.D.”): 105,954,077 for, 16,650,346 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 17,391,946 for, 966,134 withheld, 53,132 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,498,193 | 0 | 0 | 84,361 | Mixed |
| Equitable | 572,378 | 0 | 0 | 96,040 | Mixed |
| Charles Schwab | 0 | 0 | 0 | 339,215 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 125,425 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 103,000 | Withhold |
| Northern Trust | 0 | 0 | 0 | 63,216 | Withhold |
| John Hancock | 0 | 0 | 53,132 | 0 | Abstain |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 44,905 | Withhold |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 41,612 | Withhold |
| ProShares | 0 | 0 | 0 | 32,536 | Withhold |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 28,894 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 25,400 | Withhold |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 0 | 19,583 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 18,384 | Withhold |
| SEI | 0 | 0 | 0 | 16,700 | Withhold |
| Principal | 0 | 0 | 0 | 14,684 | Withhold |
| Federated Hermes | 11,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Melissa V. Rewolinski, Ph.D.
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Melissa V. Rewolinski, Ph.D.”): 111,055,063 for, 11,549,360 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 18,411,212 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,582,554 | 0 | 0 | 0 | For |
| Equitable | 668,418 | 0 | 0 | 0 | For |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 125,425 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
| Federated Hermes | 11,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Michael J. McElhaugh
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Michael J. McElhaugh”): 110,465,378 for, 12,139,045 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 18,411,212 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,582,554 | 0 | 0 | 0 | For |
| Equitable | 668,418 | 0 | 0 | 0 | For |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 125,425 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
| Federated Hermes | 11,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 2 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Richard C. Henriques
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Richard C. Henriques”): 109,654,719 for, 12,949,704 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 18,411,212 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,582,554 | 0 | 0 | 0 | For |
| Equitable | 668,418 | 0 | 0 | 0 | For |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 125,425 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
| Federated Hermes | 11,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.2% of fund votes cast · no official result
Description as filed by funds: To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended, to (a) increase the aggregate number of common shares authorized for issuance thereunder by 9,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 9,500,000 common shares;
The 35 asset managers below reported 18,274,527 for, 136,685 against, 64,726 mixed. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,582,554 | 0 | 0 | 0 | For |
| Equitable | 668,418 | 0 | 0 | 0 | For |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 0 | 125,425 | 0 | 0 | Against |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.
Combines 7 wordings of this item as funds reported it.
88% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“3. To approve, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular”): 99,284,557 for, 13,548,318 against — passed, per its Form 8-K filed May 28, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 5,603 | 0 | 3,551,932 | 0 | Abstain |
| Fidelity | 1,582,554 | 0 | 0 | 0 | For |
| Equitable | 316,121 | 0 | 352,297 | 0 | Mixed |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 0 | 125,425 | 0 | 0 | Against |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
Fund voting reports, all 35 managers: 14,372,434 for, 134,549 against, 3,904,229 abstained, 64,726 mixed. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Whitefort Capital Management, LP | 12,862,152 | 0 | 0 | 0 | For |
| Morgan Stanley | 0 | 0 | 8,070,171 | 0 | Abstain |
| Two Seas Capital LP | 0 | 7,463,977 | 0 | 0 | Against |
| BlackRock | 4,942,257 | 0 | 0 | 0 | For |
| Woodline Partners LP | 3,249,673 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 3,028,235 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,000,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,641,275 | 0 | 0 | 0 | For |
| State Street | 1,497,522 | 0 | 0 | 0 | For |
| Centiva Capital, LP | 1,322,827 | 0 | 0 | 0 | For |
| Citadel | 1,083,522 | 0 | 0 | 0 | For |
| Northern Trust | 942,361 | 233 | 0 | 0 | For |
| Corbin Capital Partners, L.P. | 847,231 | 0 | 0 | 0 | For |
| Wellington | 381,140 | 0 | 0 | 0 | For |
| BOOTHBAY FUND MANAGEMENT, LLC | 352,255 | 0 | 0 | 0 | For |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 298,260 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 285,924 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 185,721 | 0 | 0 | 0 | For |
| Vanguard | 152,466 | 0 | 0 | 0 | For |
| American Century | 0 | 125,425 | 0 | 0 | Against |
| AllianceBernstein | 96,040 | 0 | 0 | 0 | For |
| Fidelity | 95,758 | 0 | 0 | 0 | For |
| Clear Harbor Asset Management, LLC | 78,761 | 0 | 0 | 0 | For |
| RBC Dominion Securities Inc. | 66,871 | 0 | 0 | 0 | For |
Institutional-manager reports, all 91 managers: 37,432,706 for, 7,661,265 against, 8,078,114 abstained. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.5% Approved · of votes cast
Description as filed by funds: To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 146,351,847 for, 648,515 against — passed, per its Form 8-K filed May 28, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(4) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 35 asset managers below reported 18,411,212 for, 64,726 mixed.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,797,952 | 0 | 0 | 0 | For |
| BlackRock | 5,441,167 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,557,535 | 0 | 0 | 0 | For |
| Fidelity | 1,582,554 | 0 | 0 | 0 | For |
| Equitable | 668,418 | 0 | 0 | 0 | For |
| Charles Schwab | 339,215 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 236,161 | 0 | 0 | 0 | For |
| American Century | 125,425 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,000 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 63,216 | 0 | 0 | 0 | For |
| John Hancock | 53,132 | 0 | 0 | 0 | For |
| Pacific Life | 50,453 | 0 | 0 | 0 | For |
| Voya | 44,905 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 43,299 | 0 | 0 | 0 | For |
| Brighthouse | 41,612 | 0 | 0 | 0 | For |
| ProShares | 32,536 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,581 | 0 | 0 | 0 | For |
| Nationwide | 28,894 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 25,400 | 0 | 0 | 0 | For |
| Invesco | 19,699 | 0 | 0 | 0 | For |
| DWS | 19,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,384 | 0 | 0 | 0 | For |
| SEI | 16,700 | 0 | 0 | 0 | For |
| Principal | 14,684 | 0 | 0 | 0 | For |
Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 188,717,409 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.07% |
| 2 | BlackRock | 2.88% |
| 3 | Morgan Stanley | 1.89% |
| 4 | Fidelity | 0.84% |
| 5 | Equitable | 0.35% |
| 6 | Charles Schwab | 0.18% |
| 7 | QUANTITATIVE MASTER SERIES LLC | 0.13% |
| 8 | American Century | 0.07% |
| 9 | Lincoln Financial | 0.05% |
| 10 | Saba Capital Income & Opportunities Fund | 0.03% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Whitefort Capital Management, LP | 6.82% |
| 2 | Morgan Stanley | 4.28% |
| 3 | Two Seas Capital LP | 3.96% |
| 4 | BlackRock | 2.62% |
| 5 | Woodline Partners LP | 1.72% |
| 6 | Hudson Bay Capital Management LP | 1.60% |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.59% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.87% |
| 9 | State Street | 0.79% |
| 10 | Centiva Capital, LP | 0.70% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Roivant | 20.58% | DEF14A |
| Morgan Stanley | 12.96% | 13F |
| Whitefort Capital Management, LP | 6.99% | 13G |
| Blackrock, Inc. | 5.51% | DEF14A |
| Two Seas Capital LP | 4.79% | DEF14A |
| Vanguard Group | 4.76% | 13F |
| Michael J. Sofia, Ph.D. | 1.50% | DEF14A |
| State Street | 1.38% | 13F |
| Michael J. McElhaugh | 1.18% | DEF14A |
| Citadel Advisors | 1.16% | 13F |
Percentages above are of 188,717,409 shares outstanding, as reported by ARBUTUS BIOPHARMA CORP. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARBUTUS BIOPHARMA CORP.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.
At ARBUTUS BIOPHARMA CORP.'s shareholder meeting held May 22, 2024, in the 2023-2024 proxy season, 113 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,187 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — ARBUTUS BIOPHARMA CORP.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ARBUTUS BIOPHARMA CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 28, 2024.
ARBUTUS BIOPHARMA CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.